12:00 AM
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III EOS trial in 933 patients showed that once-daily 500 ug oral Daxas plus Serevent salmeterol for 24 weeks significantly improved mean pre- and post-bronchodilator FEV1 by 49 and 60 mL, respectively, vs. placebo plus Serevent (p<0.001 for each). Daxas also significantly improved pre- and post-bronchodilator FEV1/forced vital capacity (FVC) by 1.2% and 1.1%, respectively, vs. placebo (p<0.001 for each); significantly increased median time to first moderate or severe exacerbation vs. placebo (p=0.007); and significantly reduced the proportion of patients experiencing...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >